Severe hypoglycaemia and glycaemic control in Type 1 diabetes: meta‐analysis of multiple daily insulin injections compared with continuous subcutaneous insulin infusion
Open accessThe DOI matches its Crossref record; 56 of the 56 references it cites were found in a registry or an index.
Abstract
Aims Continuous subcutaneous insulin infusion (CSII) is a recommended treatment for reducing severe hypoglycaemia in Type 1 diabetes, but the change in hypoglycaemia compared with multiple daily insulin injections (MDI) is unclear. We therefore conducted a meta‐analysis comparing severe hypoglycaemia and glycaemic control during CSII and MDI. Methods Databases and literature (1996–2006) were searched for randomized controlled trials (RCTs) and before/after studies of ≥ 6 months’ duration CSII and with severe hypoglycaemia frequency > 10 episodes/100 patient years on MDI. Results In 22 studies (21 reports), severe hypoglycaemia during MDI was related to diabetes duration (P = 0.038) and was greater in adults than children (100 vs. 36 events/100 patient years, P = 0.036). Severe hypoglycaemia was reduced during CSII compared with MDI, with a rate ratio of 2.89 (95% CI 1.45 to 5.76) for RCTs and 4.34 (2.87 to 6.56) for before/after studies [rate ratio 4.19 (2.86 to 6.13) for all studies]. The reduction was greatest in those with the highest initial severe hypoglycaemia rates on MDI (P < 0.001). The mean difference in glycated haemoglobin (HbA 1c) between treatments was less for RCTs [0.21% (0.13–0.30%)] than in before/after studies [0.72% (0.55–0.90%)] but strongly related to the initial HbA 1c on MDI (P < 0.001). Conclusions The severe hypoglycaemia rate in Type 1 diabetes was markedly less during CSII than MDI, with the greatest reduction in those with most severe hypoglycaemia on MDI and those with the longest duration of diabetes. The biggest improvement in HbA 1c was in those with the highest HbA 1c on MDI.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Measuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139
Bias in meta-analysis detected by a simple, graphical test
Egger, M., Smith, G. D., Schneider, M., & Minder, C. (1997) · BMJ · doi:10.1136/bmj.315.7109.629 · Cited by 56,722
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
Publication Bias in Meta‐Analysis: Prevention, Assessment and Adjustments
(2005) · doi:10.1002/0470870168 · Cited by 2,368
Meta-analyses involving cross-over trials: methodological issues
Elbourne, D. R., Altman, D. G., Higgins, J. P., Curtin, F., Worthington, H. V., & Vail, A. (2002) · International Journal of Epidemiology · doi:10.1093/ije/31.1.140 · Cited by 2,305
Cryer, P. E., Davis, S. N., & Shamoon, H. (2003) · Diabetes Care · doi:10.2337/diacare.26.6.1902 · Cited by 1,160
Defining and Reporting Hypoglycemia in Diabetes
American Diabetes Association Workgroup on Hypoglycemia (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1245 · Cited by 1,146
Weissberg-Benchell, J., Antisdel-Lomaglio, J., & Seshadri, R. (2003) · Diabetes Care · doi:10.2337/diacare.26.4.1079 · Cited by 551
Shrier, I., Boivin, J.-F., Steele, R. J., Platt, R. W., Furlan, A., Kakuma, R., Brophy, J., & Rossignol, M. (2007) · American Journal of Epidemiology · doi:10.1093/aje/kwm189 · Cited by 493
Pickup, J., Mattock, M., & Kerry, S. (2002) · BMJ · doi:10.1136/bmj.324.7339.705 · Cited by 483
Self-citation
Cited by
Cryer, P. E., Davis, S. N., & Shamoon, H. (2003) · Diabetes Care · doi:10.2337/diacare.26.6.1902 · Cited by 1,160
Effectiveness of Sensor-Augmented Insulin-Pump Therapy in Type 1 Diabetes
Bergenstal, R. M., Tamborlane, W. V., Ahmann, A., Buse, J. B., Dailey, G., Davis, S. N., Joyce, C., Peoples, T., Perkins, B. A., Welsh, J. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002853 · Cited by 894
Handelsman, Y., Bloomgarden, Z. T., Grunberger, G., Umpierrez, G., Zimmerman, R. S., Bailey, T. S., Blonde, L., Bray, G. A., Cohen, A. J., Dagogo-Jack, S., et al. (2015) · Endocrine Practice · doi:10.4158/ep15672.gl · Cited by 629
Handelsman, Y., Bloomgarden, Z. T., Grunberger, G., Umpierrez, G., Zimmerman, R. S., Bailey, T. S., Blonde, L., Bray, G. A., Cohen, A. J., Dagogo-Jack, S., et al. (2015) · Endocrine Practice · doi:10.4158/ep15672.glsuppl · Cited by 559
Amiel, S. A., Aschner, P., Childs, B., Cryer, P. E., de Galan, B. E., Frier, B. M., Gonder-Frederick, L., Heller, S. R., Jones, T., Khunti, K., et al. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30315-2 · Cited by 526
Handelsman, Y., Mechanick, J. I., Blonde, L., Grunberger, G., Bloomgarden, Z. T., Bray, G. A., Dagogo-Jack, S., Davidson, J. A., Einhorn, D., Ganda, O., et al. (2011) · Endocrine Practice · doi:10.4158/ep.17.s2.1 · Cited by 513
Yeh, H.-C., Brown, T. T., Maruthur, N., Ranasinghe, P., Berger, Z., Suh, Y. D., Wilson, L. M., Haberl, E. B., Brick, J., Bass, E. B., et al. (2012) · Annals of Internal Medicine · doi:10.7326/0003-4819-157-5-201209040-00508 · Cited by 493
the SWITCH Study Group, Battelino, T., Conget, I., Olsen, B., Schütz-Fuhrmann, I., Hommel, E., Hoogma, R., Schierloh, U., Sulli, N., & Bolinder, J. (2012) · Diabetologia · doi:10.1007/s00125-012-2708-9 · Cited by 494
“The use of insulin pump therapy (CSII) reduces the HbA1c level without an increase in hypoglycaemia, compared with multiple daily insulin injections in meta-analyses [4, 5], and is recommended for the improvement of metabolic control [3].”
BackgroundHypoglycaemia in diabetes mellitus: epidemiology and clinical implications
Frier, B. M. (2014) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2014.170 · Cited by 481
Karges, B., Schwandt, A., Heidtmann, B., Kordonouri, O., Binder, E., Schierloh, U., Boettcher, C., Kapellen, T., Rosenbauer, J., & Holl, R. W. (2017) · JAMA · doi:10.1001/jama.2017.13994 · Cited by 452
7. Diabetes Technology: Standards of Medical Care in Diabetes—2022
American Diabetes Association Professional Practice Committee (2022) · Diabetes Care · doi:10.2337/dc22-s007 · Cited by 358
7. Diabetes Technology: Standards of Care in Diabetes—2025
American Diabetes Association Professional Practice Committee, ElSayed, N. A., McCoy, R. G., Aleppo, G., Balapattabi, K., Beverly, E. A., Briggs Early, K., Bruemmer, D., Echouffo-Tcheugui, J. B., Ekhlaspour, L., et al. (2025) · Diabetes Care · doi:10.2337/dc25-s007 · Cited by 348
Cummins, E., Royle, P., Snaith, A., Greene, A., Robertson, L., McIntyre, L., & Waugh, N. (2010) · Health Technology Assessment · doi:10.3310/hta14110 · Cited by 335
7. Diabetes Technology: Standards of Care in Diabetes — 2023
ElSayed, N. A., Aleppo, G., Aroda, V. R., Bannuru, R. R., Brown, F. M., Bruemmer, D., Collins, B. S., Hilliard, M. E., Isaacs, D., Johnson, E. L., et al. (2023) · Diabetes Care · doi:10.2337/dc23-s007 · Cited by 301
7. Diabetes Technology: Standards of Care in Diabetes—2024
American Diabetes Association Professional Practice Committee, ElSayed, N. A., Aleppo, G., Bannuru, R. R., Bruemmer, D., Collins, B. S., Ekhlaspour, L., Hilliard, M. E., Johnson, E. L., Khunti, K., et al. (2024) · Diabetes Care · doi:10.2337/dc24-s007 · Cited by 281
Insulin-pump therapy for type 1 diabetes mellitus
Pickup, J. C. (2012) · New England Journal of Medicine · doi:10.1056/nejmct1113948 · Cited by 270
Self-citationObesity in Type 1 Diabetes: Pathophysiology, Clinical Impact, and Mechanisms
Corbin, K. D., Driscoll, K. A., Pratley, R. E., Smith, S. R., Maahs, D. M., Mayer-Davis, E. J., & Advancing Care for Type 1 Diabetes and Obesity Network (ACT1ON) (2018) · Endocrine Reviews · doi:10.1210/er.2017-00191 · Cited by 262
(2015) · doi:10.1136/bmj.h3234 · Cited by 258
Hypoglycemia: The neglected complication
Kalra, S., Mukherjee, J. J., Venkataraman, S., Bantwal, G., Shaikh, S., Saboo, B., Das, A. K., & Ramachandran, A. (2013) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/2230-8210.117219 · Cited by 255
Peters, A. L., Ahmann, A. J., Battelino, T., Evert, A., Hirsch, I. B., Murad, M. H., Winter, W. E., & Wolpert, H. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-2534 · Cited by 250
Advances in technology for management of type 1 diabetes
Beck, R. W., Bergenstal, R. M., Laffel, L. M., & Pickup, J. C. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31142-0 · Cited by 242
Self-citationLittle, S. A., Leelarathna, L., Walkinshaw, E., Tan, H. K., Chapple, O., Lubina-Solomon, A., Chadwick, T. J., Barendse, S., Stocken, D. D., Brennand, C., et al. (2014) · Diabetes Care · doi:10.2337/dc14-0030 · Cited by 237
Choudhary, P., Rickels, M. R., Senior, P. A., Vantyghem, M.-C., Maffi, P., Kay, T. W., Keymeulen, B., Inagaki, N., Saudek, F., Lehmann, R., et al. (2015) · Diabetes Care · doi:10.2337/dc15-0090 · Cited by 233
Coming of age: the artificial pancreas for type 1 diabetes
Thabit, H., & Hovorka, R. (2016) · Diabetologia · doi:10.1007/s00125-016-4022-4 · Cited by 223
“Insulin analogues and modern insulin regimens, including insulin pump therapy, have lowered the relative risk of hypoglycaemia compared with those observed in the intensive insulin treatment group of the transformative Diabetes Control and Complication Trial [16, 19, 20] but inherent unpredictability and variability o…”
7. Diabetes Technology: Standards of Medical Care in Diabetes—2021
American Diabetes Association (2021) · Diabetes Care · doi:10.2337/dc21-s007 · Cited by 202
ISPAD Clinical Practice Consensus Guidelines 2018: diabetes technologies
Sherr, J. L., Tauschmann, M., Battelino, T., de Bock, M., Forlenza, G., Roman, R., Hood, K. K., & Maahs, D. M. (2018) · Pediatric Diabetes · doi:10.1111/pedi.12731 · Cited by 197
7. Diabetes Technology: Standards of Medical Care in Diabetes—2019
American Diabetes Association (2019) · Diabetes Care · doi:10.2337/dc19-s007 · Cited by 179
Insulin therapy and hypoglycemia
McCall, A. L. (2012) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2012.03.001 · Cited by 177
Insulin Pump Therapy With Automated Insulin Suspension in Response to Hypoglycemia
Choudhary, P., Shin, J., Wang, Y., Evans, M. L., Hammond, P. J., Kerr, D., Shaw, J. A. M., Pickup, J. C., & Amiel, S. A. (2011) · Diabetes Care · doi:10.2337/dc10-2411 · Cited by 175
“This is similar to results with insulin pump therapy providing the greatest reduction in hypoglycemia in those with the most hypoglycemia at baseline (7).”
ResultSelf-citationISPAD Clinical Practice Consensus Guidelines 2022: Diabetes technologies: Insulin delivery
Sherr, J. L., Schoelwer, M., Dos Santos, T. J., Reddy, L., Biester, T., Galderisi, A., van Dyk, J. C., Hilliard, M. E., Berget, C., & DiMeglio, L. A. (2022) · Pediatric Diabetes · doi:10.1111/pedi.13421 · Cited by 152
Insulin Infusion Set: The Achilles Heel of Continuous Subcutaneous Insulin Infusion
Heinemann, L., & Krinelke, L. (2012) · Journal of Diabetes Science and Technology · doi:10.1177/193229681200600429 · Cited by 153
Nonmetabolic Complications of Continuous Subcutaneous Insulin Infusion: A Patient Survey
Pickup, J. C., Yemane, N., Brackenridge, A., & Pender, S. (2014) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2013.0192 · Cited by 123
Self-citationBeck, R. W., Riddlesworth, T. D., Ruedy, K. J., Kollman, C., Ahmann, A. J., Bergenstal, R. M., Bhargava, A., Bode, B. W., Haller, S., Kruger, D. F., et al. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30217-6 · Cited by 119
Bolli, G. B., Kerr, D., Thomas, R., Torlone, E., Sola-Gazagnes, A., Vitacolonna, E., Selam, J. L., & Home, P. D. (2009) · Diabetes Care · doi:10.2337/dc08-1874 · Cited by 119
Pala, L., Dicembrini, I., & Mannucci, E. (2019) · Acta Diabetologica · doi:10.1007/s00592-019-01326-5 · Cited by 112
Smith, C. B., Choudhary, P., Pernet, A., Hopkins, D., & Amiel, S. A. (2009) · Diabetes Care · doi:10.2337/dc08-2259 · Cited by 106
Tumminia, A., Crimi, S., Sciacca, L., Buscema, M., Frittitta, L., Squatrito, S., Vigneri, R., & Tomaselli, L. (2015) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2557 · Cited by 100
Managing diabetes in preschool children
Sundberg, F., Barnard, K., Cato, A., de Beaufort, C., DiMeglio, L. A., Dooley, G., Hershey, T., Hitchcock, J., Jain, V., Weissberg-Benchell, J., et al. (2017) · Pediatric Diabetes · doi:10.1111/pedi.12554 · Cited by 91
Randomized Trial of Infusion Set Function: Steel Versus Teflon
Patel, P. J., Benasi, K., Ferrari, G., Evans, M. G., Shanmugham, S., Wilson, D. M., & Buckingham, B. A. (2014) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2013.0119 · Cited by 90
“Meta-analyses of CSII therapy compared with multiple daily injections therapy have shown a modest improvement in glycemic control and a lower incidence of hypoglycemia with CSII therapy.(1,2) Major disadvantages of pump use include infusion set failure, which can lead to hyperglycemia and diabetic ketoacidosis, and lo…”
MethodLittle, S. A., Speight, J., Leelarathna, L., Walkinshaw, E., Tan, H. K., Bowes, A., Lubina-Solomon, A., Chadwick, T. J., Stocken, D. D., Brennand, C., et al. (2018) · Diabetes Care · doi:10.2337/dc17-2682 · Cited by 86
Roze, S., Smith‐Palmer, J., Valentine, W., de Portu, S., Nørgaard, K., & Pickup, J. C. (2015) · Diabetic Medicine · doi:10.1111/dme.12792 · Cited by 77
Self-citationEvaluation of Pump Discontinuation and Associated Factors in the T1D Exchange Clinic Registry
Wong, J. C., Boyle, C., DiMeglio, L. A., Mastrandrea, L. D., Abel, K.-L., Cengiz, E., Cemeroglu, P. A., Aleppo, G., Largay, J. F., Foster, N. C., et al. (2017) · Journal of Diabetes Science and Technology · doi:10.1177/1932296816663963 · Cited by 69
Neinstein, A., Wong, J., Look, H., Arbiter, B., Quirk, K., McCanne, S., Sun, Y., Blum, M., & Adi, S. (2016) · Journal of the American Medical Informatics Association · doi:10.1093/jamia/ocv104 · Cited by 66
Improved A1C Levels in Type 1 Diabetes with Smartphone App Use
Ryan, E. A., Holland, J., Stroulia, E., Bazelli, B., Babwik, S. A., Li, H., Senior, P., & Greiner, R. (2017) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2016.06.001 · Cited by 63
Restoration of Self-Awareness of Hypoglycemia in Adults With Long-Standing Type 1 Diabetes
Leelarathna, L., Little, S. A., Walkinshaw, E., Tan, H. K., Lubina-Solomon, A., Kumareswaran, K., Lane, A. P., Chadwick, T., Marshall, S. M., Speight, J., et al. (2013) · Diabetes Care · doi:10.2337/dc13-1004 · Cited by 56
“Use of continuous subcutaneous insulin infusion (CSII) is reported to reduce SH (22), but relatively few studies have compared CSII with modern long-acting analog insulins, such as insulin glargine as the basal insulin (23,24).”
BackgroundThe role of continuous subcutaneous insulin infusion therapy in patients with diabetic gastroparesis
Sharma, D., Morrison, G., Joseph, F., Purewal, T. S., & Weston, P. J. (2011) · Diabetologia · doi:10.1007/s00125-011-2282-6 · Cited by 53
“A recent meta-analysis has established that the rate of episodes of severe hypoglycaemia in type 1 diabetes is reduced by CSII, leading to improvements in HbA1c [6].”
BackgroundChoudhary, P., & Amiel, S. A. (2018) · Diabetologia · doi:10.1007/s00125-018-4566-6 · Cited by 52
“Participants received structured education and were randomised to receive insulin by either CSII or MDI.”
InfluentialEvolution of Devices in Diabetes Management
Penfornis, A., Personeni, E., & Borot, S. (2011) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2011.0058 · Cited by 49
“17,19,25 Although CSII offers several benefits over MDI, it may also be associated with a higher, albeit still relatively low, rate of diabetic ketoacidosis.”
Little, S. A., Leelarathna, L., Barendse, S. M., Walkinshaw, E., Tan, H. K., Lubina Solomon, A., de Zoysa, N., Rogers, H., Choudhary, P., Amiel, S. A., et al. (2014) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2492 · Cited by 48
“A more focused review that only included studies of at least 6 months duration where the rate of severe hypoglycaemia during MDI was >10 episodes/100 patient years of treatment suggested that CSII is significantly better than MDI in reducing the risk of severe hypoglycaemia [115].”
BackgroundHeise, T., Meiffren, G., Alluis, B., Seroussi, C., Ranson, A., Arrubla, J., Correia, J., Gaudier, M., Soula, O., Soula, R., et al. (2019) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13621 · Cited by 40
Ghandi, K., Pieri, B., Dornhorst, A., & Hussain, S. (2021) · Diabetes Therapy · doi:10.1007/s13300-020-00965-0 · Cited by 34
Clinical approaches to treat impaired awareness of hypoglycaemia
Farrell, C. M., & McCrimmon, R. J. (2021) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188211000248 · Cited by 31
Boulet, G., Halpern, E. M., Lovblom, L. E., Weisman, A., Bai, J.-W., Eldelekli, D., Keenan, H. A., Brent, M. H., Paul, N., Bril, V., et al. (2016) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2015.0216 · Cited by 26
Taleb, N., Messier, V., Ott-Braschi, S., Ardilouze, J.-L., & Rabasa-Lhoret, R. (2018) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2018.07.035 · Cited by 25
González-Molero, I., Domínguez-López, M., Guerrero, M., Carreira, M., Caballero, F., Rubio-Martín, E., Linares, F., Cardona, I., Anarte, M. T., de Adana, M. S. R., et al. (2012) · Journal of Telemedicine and Telecare · doi:10.1258/jtt.2012.120103 · Cited by 24
Meunier, L., Aguadé, A.-S., Videau, Y., Verboux, D., Fagot-Campagna, A., Gastaldi-Menager, C., & Amadou, C. (2021) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2020.0112 · Cited by 22
Bratke, H., Margeirsdottir, H. D., Assmus, J., Njølstad, P. R., & Skrivarhaug, T. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01127-6 · Cited by 20
“It has been proposed that a low baseline HbA1c level leads to minimal changes, whereas a high baseline HbA1c level generally markedly lowers HbA1c levels in CSII users [28, 29].”
BackgroundAleppo, G., DeSalvo, D. J., Lauand, F., Huyett, L. M., Chang, A., Vienneau, T., & Ly, T. T. (2023) · Diabetes Therapy · doi:10.1007/s13300-023-01366-9 · Cited by 19
Rosenlund, S., Hansen, T. W., Rossing, P., & Andersen, S. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-2839 · Cited by 19
Pfützner, A., Weissmann, J., Mougiakakou, S., Daskalaki, E., Weis, N., & Ziegler, R. (2015) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2014.0278 · Cited by 19
Hoshina, S., Andersen, G. S., Jørgensen, M. E., Ridderstråle, M., Vistisen, D., & Andersen, H. U. (2018) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2017.0231 · Cited by 18
Lombardo, F., Scaramuzza, A. E., & Iafusco, D. (2012) · Acta Diabetologica · doi:10.1007/s00592-011-0344-3 · Cited by 15
Botros, S., Islam, N., & Hursh, B. (2019) · Pediatric Diabetes · doi:10.1111/pedi.12834 · Cited by 6
Metadata
- Authors
- Pickup, J. C., & Sutton, A. J.
- Venue
- Diabetic Medicine
- Publisher
- Wiley
- Published
- 2008-07
- Volume
- 25
- Issue
- 7
- Pages
- 765-774
- ISSN
- 0742-3071 (ISSN-L)
- 1464-5491
- OpenAlex
- W2037385875
- Cited by
- 617
- References
- 56
- FWCI
- 23.97
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.